In addition to substantial price reduction, Eli Lilly said it would launch on April 1 a new insulin product called Rezvoglar — a copycat version of Sanofi’s Lantus insulin.

New Delhi: There is excitement and hope in the insulin market the world over after U.S. based pharma giant Eli Lilly & Company on Monday announced results of its “successful” late-stage trial ...

Eli Lilly CEO says insulin tweet flap “probably” signals need to bring down cost "We’re obviously not the only insulin company. But the tropes go on," he said.

Positive preliminary results for Eli Lilly’s efsitora alfa continue to build the case for this once-weekly insulin in type 2 diabetes patients. Lilly is trying to catch up to Novo Nordisk’s ...

Eli Lilly and Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On June 22, Eli Lilly and ...

Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay to fill prescriptions. Lilly said it will cut the list price for its ...

Eli Lilly (LLY) stock will be in focus as two phase 3 trials for its once-weekly insulin efsitora alfa succeed against daily basal insulins. Read more here.

Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly & Co.'s experimental once-weekly insulin can lower ...

Eli Lilly’s once-weekly insulin injection is just as effective as daily insulin shots for managing A1C levels in diabetes, according to the latest results from two phase 3 clinical trials.

A pair of late-stage trials found that Eli Lilly’s experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday, intensifying ...